The immunogenicity and safety of different COVID-19 booster vaccination following

CoronaVac or ChAdOx1 nCoV-19 primary series

Nasikarn Angkasekwinai[1], Suvimol Niyomnaitham[2,3], Jaturong Sewatanon[4], Supaporn

Phumiamorn[5], Kasama Sukapirom[6,7], Sansnee Senawong[8], Surakameth Mahasirimongkol[5],

Zheng Quan Toh[9], Pinklow Umrod[8], Thitiporn Somporn[5], Supaporn Chumpol[5], Kanokphon

Ritthitham[5], Kulkanya Chokephaibulkit[3,10*]

[1]Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[2]Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University,

Thailand

[3]Siriraj Institute of Clinical Research (SICRES), Mahidol University, Thailand

[4]Department of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University,

Thailand

[5]Department of Medical Sciences, Ministry of Public Health, Thailand

[6]Biomedical Research Incubator Unit, Department of Research, Faculty of Medicine Siriraj

Hospital, Mahidol University, Thailand

[7]Siriraj Center of Research Excellence in Microparticle and Exosome in Disease, Thailand

[8]Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

[9]Murdoch Children's Research Institute, Parkville, VIC 3052, Australia

[10]Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

Corresponding author:

Kulkanya Chokephaibulkit, MD

Professor of Pediatrics,

Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University

Siriraj Institute of Clinical Research (SICRES)

2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand

Tel: (+66) 2-4141899; Fax: (+66) 2-4128243

E-mail: kulkanya.cho@mahidol.ac.th

Nasikarn Angkasekwinai and Suvimol Niyomnaitham equally contributed to the research work.

Abstract word count: 149

Manuscript Text word count: 3569

Abstract

The appropriate COVID-19 booster vaccine following inactivated or adenoviral vector COVID-

19 vaccination is unclear. We evaluated the safety and immunogenicity of different booster

vaccines, inactivated (BBIBP-CorV), chimpanzee adenoviral vector (ChAdOx1), or mRNA

(BNT162b2 at full (30 µg), or half (15 µg) dose) in healthy adults who received 2-dose primary

series of either inactivated vaccine (CoronaVac) or ChAdOx1 8-12 weeks earlier. Overall, the

adverse events for all booster vaccines were mild and moderate. Two weeks post-booster dose, the

neutralising antibody titres against Delta variant in CoronaVac-prime and ChAdOx1-prime were

highest with for 30µg-BNT162b2 (411 vs 470) and 15µg-BNT162b2 (499 vs 358); followed by

ChAdOx1 (271 vs 69), and BBIBP-CorV (61.3 vs 49). BNT162b2 also induced higher interferon

gamma response. Heterologous COVID-19 boosting vaccination with BNT162b2 is the most

immunogenic following CoronaVac or ChAdOx1 primary series. A lower dose BNT162b2 may

be used as booster in settings with limited vaccine supply.

Introduction

Both CoronaVac (an inactivated whole-virion SARS-CoV-2 vaccine, Sinovac Life Science) and ChAdOx1 (a chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein, Oxford, AstraZeneca) are safe and effective against symptomatic COVID-19 caused by the ancestral Wuhan strain, and to a lower extent against the delta variant[1-7]. These two vaccines are among the most widely used vaccines in low- and middle-income countries and some high-income countries.

There are increasing reports of breakthrough infections following COVID-19 vaccination, which is likely due to a combination of waning immunity and the emergence of SARS-CoV-2 variants, particularly the delta variant[8-11]. While the antibody threshold of protection has not been identified, higher antibody levels are likely to be associated with greater protection, including the variants[7]. Furthermore, cell mediated immune responses (CMIR) generated following vaccination are also likely to play an important role in protection.

Several studies have demonstrated improved humoral responses with heterologous COVID-19 prime-boost vaccination, primarily on ChAdOx1 and mRNA vaccines[12-16]. However, other combinations of prime-boost COVID-19 vaccination involving inactivated COVID-19 vaccines have not been evaluated. A recent study of reduced dosage of a booster shot of mRNA-1273 vaccine was found to be highly immunogenic[17]. It is therefore possible that the dosage required for booster may be less than the primary series, particularly with the highly immunogenic vaccine like mRNA vaccines. Reduced dosage of the vaccine will therefore increase accessibility, reduced cost, and could be an important strategy for public health to control the outbreak.

In this study, we examined the immunogenicity and safety of different booster vaccine platforms and reduced dosages (BBIBP-CorV, inactivated vaccine manufactured by Sinopharm;

ChAdOx1, chimpanzee adenoviral vector vaccine manufactured by AstraZeneca/Oxford; full dose

(30 µg) BNT162b2, mRNA vaccine manufactured by Pfizer; and half dose (15 µg) BNT162b2) in

healthy adults aged 18-60 years who received a 2-dose primary series of CoronaVac 4 weeks apart

(CoronaVac-prime) or ChAdOx1 vaccine 8-10 weeks apart (ChAdOx1-prime).

Results

A total of 352 participants were enrolled (179 and 173 participants in CoronaVac- and

ChAdOx1-prime group), 285 (81%) were female, and the median age was 39 (interquartile range,

IQR: 31-47) years. The demographic of the study participants receiving different booster vaccine

was shown in Table 1.

Adverse events (AEs)

Among CoronaVac-prime group, the frequency of overall AEs was the highest after

boosting with ChAdOx1 (98%), followed by 30 µg BNT162b2 (92%), 15 µgBNT162b2 (80%),

and BBIBP-CorV (70%); whereas in ChAdOx1-prime group, the highest rate of overall AEs was

reported after boosting with 30 µg BNT162b2 (98%), followed by 15 µgBNT162b2 (88%),

ChAdOx1 (72%), and BBIBP-CorV (61%) (Fig. 1, Supplementary Table 1). Systemic AEs were

in the same trend as local AEs. All AEs were mild (grade 1) or moderate (grade 2) in severity and

recovered within 2-3 days. No serious AEs was found in this study.

Anti-SARS-CoV-2 RBD IgG responses

Prior to the booster dose (8-12 weeks post-primary series), 175/179 (97.8%) participants

in CoronaVac-prime and all (172/173, 99.4%) in ChAdOx1-prime were seropositive; however, the

anti-RBD IgG geometric mean concentrations (GMCs) were lower in CoronaVac-prime group

than ChAdOx1-prime group (36.31 BAU/mL range: 33-38 BAU/mL vs 98.27 BAU/mL, range:

90-116 BAU/mL) (Fig. 2A). For the CoronaVac-prime group, at 2 weeks after the booster

vaccination, the anti-RBD IgG GMC in the 30 µg BNT162b2 group (5,152 BAU/mL) was

significantly higher than other booster vaccine groups: 15 µg BNT162b2 (3,981 BAU/mL),

ChAdOx1 (1,358 BAU/mL), and BBIBP-CorV (154 BAU/mL) (Fig. 2A). A booster dose of

BBIBP, ChAdOx1, 30µg BNT162b2 or 15µg BNT162b2 increased anti-RBD IgG GMC by 4.5,

35.6, 154.7, and 105.7 times from baseline, respectively. The geometric mean ratio (GMR, 95%

CI) between post-boost and post-primary series of CoronaVac were 0.94 (0.53, 1.67) for BBIBP-

CorV, 8.26 (6.29, 10.85) for ChAdOx1, 31.34 (24.37, 40.30) for 30µg BNT162b2, and 24.22

(18.60, 31.54) for 15µg BNT162b2, respectively (Supplementary Table 2).

For the ChAdOx1-prime group, at 2 weeks after the booster dose, the anti-RBG IgG GMC

was highest in the participants receiving a booster dose of 30 µg BNT162b2 at the level of 2,364

BAU/mL, followed by 15 µgBNT162b2 (1,962 BAU/mL), ChAdOx1 (246.4 BAU/mL), and

BBIBP-CorV (128.1 BAU/mL). However, there was no statistical difference in the anti-RBD IgG

GMC between 30 µg and 15 µg BNT162b2 groups (*P*=0.1381) (Fig. 2B). A booster dose of

BBIBP, ChAdOx1, 30µg BNT162b2, or 15µg BNT162b2 increased GMCs for 1.2, 2.3, 25.1, and

21.8 times from baseline, respectively. The GMR (95% CI) between post-boost and post-primary

series of ChAdOx1 were 0.46 (0.28, 0.65) for BBIBP-CorV, 0.88 (0.58, 1.13) for ChAdOx1, 8.49

(5.71, 10.44) for 30µg BNT162b2, and 7.04 (4.69, 8.84) for 15µg BNT162b2, respectively

(Supplementary Table 2). The post-boost GMC levels in ChAdOx1-prime group were generally

lower than those in the CoronaVac-prime group for all booster vaccines. (Fig. 2C).

Neutralising antibody response against SARS-CoV-2 variants

The PRNT$_{50}$ GMTs against the Delta variant among CoronaVac-prime participants were

highest after a booster dose of 15 µg BNT162b2 (499.1), followed by 30 µg BNT162b2 (411.1),

ChAdOx1 (271.2), and BBIBP-CorV (61.3); whereas among ChAdOx1-prime group, the highest

PRNT$_{50}$ GMT was after a booster dose of 30 µg BNT162b2 (470), followed by 15 µg BNT162b2

(358.4), ChAdOx1 (69.1), and BBIBP-CorV (49.1) (Fig. 3A). A similar trend was observed for

PRNT$_{50}$ GMT against the Beta variant (Fig. 3B). There was no statistical difference of PRNT$_{50}$

GMT between boosting with 30 µg and 15 µg BNT162b2 regardless of the vaccine given as

primary series and the type of variants. The PRNT$_{50}$ GMT of the Beta variants were around 1.5-

fold lower than the Delta variants for both CoronaVac-prime and ChAdOx1-prime groups (Fig.

3C). The GMRs (95% CI) of PRNT$_{50}$ titres between post-boost and post-primary series were

highest among the participants who received BNT162b2 boosting vaccination in both CoronaVac-

prime and ChAdOx1-prime groups for both Delta and Beta variants (Table 2). The anti-SARS-

CoV-2 RBD IgG levels and the PRNT$_{50}$ titres against Delta variant (Fig. 4A and Fig. 4B) or Beta

variant (Fig. 4C and Fig. 4D) were highly correlated (r = 0.49-0.89) particularly in the ChAdOx1-

primed group.

Interferon gamma responses (Interferon gamma release assay, IGRA)

At 8-12 weeks following the primary series, 62/173 (35.8%) of participants in ChAdOx1-

prime group had positive IGRA, while only 45/179 (25%) CoronaVac-prime group was positive

(*P*=0.029). Among those who were seronegative in both CoronaVac-prime and ChAdOx1-prime

group, IGRA conversion was the highest after a booster dose of 30 µg BNT162b2, followed by 15

µg BNT162b2, ChAdOx1, and BBIBP-CorV (Table 1). Interestingly, none of the study

participants who were IGRA‑negative at baseline in theChAdOx1‑prime group had a positive

IGRA response following boosting with BBIBP‑CorV or ChAdOx1 (Table 1) (Supplementary

Fig. S1).

Discussion

In this study, we found that BBIBP-CorV, ChAdOx1, BNT162b2 (standard and reduced

dosage) given as booster dose to individuals who received either CoronaVac or ChAdOx1 primary

series were safe and immunogenic. BNT162b2 as a booster vaccine induced the highest humoral

and cellular immunity compared to BBIBP-CorV or ChAdOx1. An interesting observation was

the higher immune responses in the CoronaVac-primed group compared to the ChAdOx1-prime

group when boosting with BNT162b2 at the similar interval after primary series.

Booster vaccinations using BBIBP-CorV, ChAdOx1, BNT162b2 (standard and reduced

dosage) was safe and well tolerated, although the overall proportion who reported AEs (61-98%)

were high, particularly among BNT162b2 recipients, as well as among ChAdOx1 who received it

as the first time among CoronaVac-prime group. All AEs were mild or moderate in severity and

no serious AEs was reported. These AEs rates were similar to those reported in COVID-19 vaccine

primary series and booster studies[17-18]. The AEs frequencies following ChAdOx1 and BBIBP-

CorV in this study were consistent with those reported in the primary series vaccination in this

population[7].

Heterologous boosting vaccination in our study were found to be more immunogenic than

homologous boosting regimen of ChAdOx1 or homologous vaccine platforms (CoronaVac prime-

BBIBP-CorV boost; inactivated vaccines). The higher humoral immune responses following

heterologous ChAdOx1 prime-BNT162b2 boost vaccination compared to homologous ChAdOx1

prime-ChAdOx1 boost vaccination observed in our study was consistent with what was reported

in a cohort study[19]. However, no clinical studies have yet to report on the heterologous boosting

responses involving CoronaVac for us to verify our findings. The significant increase in

neutralising antibodies against Delta and Beta variants following boosting with BNT162b2

suggests that heterologous boosting with BNT162b2 is likely to be protective against these

variants. However, an interesting finding was that individuals in the ChAdOx1-prime group had a

blunted neutralising antibody response against the Delta and Beta variants following BBIBP-CorV

or ChAdOx1 booster. This suggests that BBIBP-CorV or ChAdOx1 given as a booster to

individuals who received ChAdOx1 as primary series may not offer additional protection against

the Delta variant that is widely circulating globally. However, the number of participants for this

analysis was small and larger studies are needed to verify this finding.

While neutralising antibodies are thought to be the primary mechanism of protection[7],

virus-specific memory T cells are also important for protection. Only a third of ChAdOx1-prime

and a quarter of CoronaVac-prime participants in our study had positive IGRA 8-12 weeks post

primary series, suggesting that CoronaVac induce a poorer T cell memory response than

ChAdOx1. Previous studies evaluating 2-dose ChAdOx1 primary series have reported the

generation of robust T cell responses (measured by interferon gamma ELISPOT) 14 days

following the first dose, with no significant increase in T cell responses following the second

dose[20-21]. The discrepancy in T cell responses from our study could be due to waning immunity,

population differences and the different assays used to measure interferon gamma response

(Quantiferon vs inteferon gamma ELISPOT). Interestingly, boosting with standard or reduced

dosage BNT162b2 induce robust T cell responses, whereas boosting with BBIBP or homologous

boosting regimen of ChAdOx1 (third dose) appears to be a poor inducer of T cell responses. It is

important to note that inactivated vaccine (i.e. BBIBP) may have other antigens (i.e. M or N

proteins) that induce T cell responses[22], whereas in our study, we only examined T cell responses

to S protein, and thus may have underestimated the cellular responses. The low T cell boosting

responses following homologous boosting regimen of ChAdOx1 is in line with the low neutralising

antibody boosting responses against the Delta and Beta variants observed in this study. This could

be explained by the anti-vector interference because of the primary vaccination, although more

studies are needed to confirm this finding.

Our findings in both vaccine-prime groups suggested that less amount of antigen may be

sufficient for boosting. We found that half-dose of 15 µg BNT162b2 was equally immunogenic as

the standard dose of 30 µg, but with less reactogenicity. This is in concordance with a study on

mRNA1273 vaccine where a booster dose of mRNA1273 vaccine at half the normal dosage (50

µg) was able to induce significantly higher neutralising antibodies than the level induced following

primary series and against the VOCs[17]. Taken together, a lower mRNA vaccine dose may be an

option for COVID-19 booster vaccination given the limited vaccine supply. However, the

persistence of immunity and the efficacy following reduced dosages in booster vaccination

remains to be determined.

There are some limitations in this study. First, our study was conducted in an open label

manner due to the availability of each vaccine at a different timing. While this may lead to selection

bias and subjective outcomes such as AEs, the demographic characteristics of the participants in

the booster groups were very similar, suggesting that this is unlikely to influence our findings.

Second, our sample size is small, particularly those who received BBIBP as booster, and therefore,

the data need to be interpreted with caution. Furthermore, it is unclear if similar findings will be

found if the duration between the last dose of primary series and the booster dose is >12 weeks (8-

12 weeks in this study). Last, the participants in this study were healthy adults therefore results

may not be generalisable to other populations such as elderly or those with underlying diseases.

In conclusion, we found that a booster dose of BNT162b2 given to individuals previously

vaccinated with CoronaVac or ChaAdOx1 primary series is the most immunogenic. Our study

findings have important implications on the choice of booster dose following CoronaVac or

ChAdOx1 primary series, and are most relevant for countries that have introduced these vaccines

to date. Furthermore, our study indicates that reduced dosage of BNT162b2 may be used as a

booster dose instead of the standard dosage. This will aid in improving global access to COVID-

19 vaccines.

Methods

Study design and participants

This single-center prospective cohort study enrolled 352 healthy adults aged 18-60 years

of age at Siriraj Hospital, a university-based referral center in Bangkok, Thailand, from March to

September 2021. The eligible participants were those who have received either 2-dose 4 weeks

apart of CoronaVac or 8-10 weeks apart of ChAdOx1 primary series vaccination in the period of

8-12 weeks prior the screening day. The exclusion criteria were history of SARS-CoV-2 infection;

received prior administration of current prophylactic treatment or investigational agents against

COVID-19 within 90 days; had an unstable underlying disease; history of vaccine anaphylaxis;

being pregnant; immunocompromised or currently receiving immunosuppressive agents. The

study procedures, risks, and benefits were explained to all participants before obtaining written

informed consent. The study protocol was approved by the Siriraj Institutional Review Board

(COA no. Si 537/2021). The procedures in this study adhere to the tenets of the Declaration of

Helsinki.

Study Procedures

The participants with prior 2-dose primary series of CoronaVac (CoronaVac-prime) or

ChAdOx1 (ChAdOx1-prime) were openly assigned to receive one of the four intramuscular

booster vaccinations: BBIBP-CorV (manufactured by Sinopharm), ChAdOx1, full dose (30 µg)

BNT162b2 (manufactured by Pfizer), and half dose (15 µg) BNT162b2. Prior to enrollment, the

potential participants who were interested to participate were provided an on-line questionnaire to

select their first and second choice of booster vaccine which will be available at the time. The

assigned booster vaccine was matched with the indicated pre-enrollment choice and the

availability of the vaccine on the study day.

The participants were observed for at least 30 min following vaccination for any immediate

adverse events (AE). Participants were instructed to record self-assessment signs or symptoms in

an electronic diary (eDiary) for seven days after vaccination to track AE including solicited local

and systemic adverse reactions. An AE in this study will be defined as any unfavorable or

unexpected sign, symptom, or disease (including an unexpected finding in a laboratory evaluation)

that occurs in any participant whether it is related to the vaccination product. Solicited local AE

included pain, erythema, and swelling/induration at the injection site, and localized axillary

swelling or tenderness ipsilateral to the injection arm. Solicited systemic AE were headache,

fatigue, myalgia, arthralgia, nausea, vomiting, rash, fever, and chills. The severity of solicited AE

were graded using a numerical scale from 1 to 4 based on two guides; Toxicity Grading Scale for

Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials from the

United States Food and Drug Administration (FDA), and in the Common Terminology Criteria for

Adverse Events - Version 5.0 guide by the United States National Cancer Institute (NCI / NIH).

Blood samples were collected at baseline (pre-booster), and two weeks after booster

vaccination (post-boost) to determine the level of antibody response (IgG) against receptor binding

domain (RBD) of the SARS-CoV-2 S1 subunit spike protein (anti-RBD IgG) and 50% plaque

reduction neutralisation test (PRNT$_{50}$) against Delta (B1.1617.2) and Beta (B.1.351) variants. The

whole blood samples were collected for cellular immunity testing by the QuantiFERON SARS-

CoV-2 interferon gamma release assay (IGRA) at baseline. The participants who had IGRA levels

below the cut-off point were tested again at 2 weeks following the booster vaccination.

Chemiluminescent microparticle assay (CMIA) for anti-SARS-CoV-2 RBD IgG

The plasma samples were stored at -80ºC until testing in batch. The anti-RBD IgG was

quantitatively measured by CMIA using the SARS-CoV-2 IgG II Quant (Abbott, List No. 06S60)

on the ARCHITECT i System. This assay linearly measures the level of antibody between 21.0 -

40,000.0 arbitrary unit (AU)/mL, which was converted later to WHO international standard

concentration as binding antibody unit per mL (BAU/mL) following the equation provided by the

manufacturer (BAU/mL =0.142 x AU/mL). The level greater or equal to the cutoff value of 50

AU/mL or 7.1 BAU/mL was defined as seropositive. Seroconversion was determined as becoming

seropositive in those who had seronegative at baseline or increase of 4-fold titres above the

baseline seropositive levels.

50% plaque reduction neutralisation test (PRNT$_{50}$)

The standard live virus 50% plaque reduction neutralisation test (PRNT$_{50}$) against Delta

variant (B.1.617.2) and Beta variant (B.1.351) were performed. Vero cells were seeded at 2x

10^5 cells/well/ 3 ml and placed in 37°C, 5% CO_2 incubator for 1 day. Test sera were initially diluted

at 1:10, 1:40, 1:160 and 1:640, respectively. SARS-CoV-2 virus was diluted in culture medium to

yield 40-120 plaques/well in the virus control wells. Cell control wells, convalescent patient serum

and normal human serum were also included as assay controls. The neutralisation was performed

by mixing the equal volume of diluted serum and the optimal plaque numbers of SARS CoV-2

virus at 37˚C in water bath for 1 h. After removing the culture medium from Vero cell culture

plates, 200 ul of the virus-serum antibody mixture were inoculated into monolayer cells and then

rocked the culture plates every 15 min for 1 h. Three ml of overlay semisolid medium (containing

1% of carboxymethylcellulose, Sigma Aldrich, USA, with 1% of 10,000 units/ml penicillin,

10,000 ug/ml streptomycin (Sigma, USA), and 10% FBS) were replaced after removing excessive

viruses. All plates were incubated at 37˚C, 5% CO_2 for 7 days. Cells were fixed with 10% (v/v)

formaldehyde then stained with 0.5% crystal violet in PBS. The number of plaques formed was

counted in triplicate wells and percentage of plaque reduction at 50% ($PRNT_{50}$) was calculated.

The $PRNT_{50}$ titre of test sample is defined as the reciprocal of the highest test serum dilution for

which the virus infectivity is reduced by 50% when compared with the average plaque counts of

the virus control and was calculated by using a four-point linear regression method. Plaque counts

for all serial dilutions of serum were scored to ensure that there was a dose response.

QuantiFERON SARS-CoV-2 interferon gamma release assay (IGRA)

SARS-CoV-2 specific T cell responses were assessed by whole blood IGRA using

QIAGEN's proprietary mixes of SARS-CoV-2 S protein following manufacture's instruction.

Briefly, whole blood samples were collected into the unstimulated tube as negative control and

stimulated tubes containing SARS-CoV-2 S peptide designed for $CD4^+$ T cell (Ag.1), for $CD8^+$ T

cells (Ag.2) and for mitogen as positive control. The specimen was incubated at 37 °C for 16-24

hours and centrifuged to separate plasma. Interferon-gamma (IFN-ϒ) concentration in the plasma

fraction was measured with an automated QuantiFERON SARS-CoV-2 ELISA instrument for

research use only (RUO) and reported in International Units per mL (IU/mL)[23-24]. The cut-off for

positivity was determined as the level above the mean plus three standard deviations of the

negative control. Using 61 negative controls at the study site, the cut-offs for Ag1 and Ag2 were

>0.12 IU/mL and >0.17 IU/mL, respectively. A positive response to either of the two peptides

pools was considered positive.

Statistical Analysis

The AEs endpoints were presented as frequencies and Chi-square test was used to test for

statistical difference. The immunological endpoints including anti-SARS-CoV-2 RBD IgG

concentration and $PRNT_{50}$ titres at 2 weeks after booster vaccination (post-boost) were reported

as geometric mean concentration (GMC) with 95% confidence interval (CI) if the data was

positively skewed. The $PRNT_{50}$ titres below 10 were arbitrarily assigned a value of 5. We used the

anti-RBD IgG GMC and the $PRNT_{50}$ geometric mean titres (GMT) at two weeks after the second

dose of primary series vaccination (post-primary series) from our previous study as the references

for comparison. The post-primary anti-RBD IgG GMC levels was 164.4 BAU/mL and 278.5

BAU/mL in 2-dose CoronaVac and ChAdOx1, respectively, while the respective $PRNT_{50}$ GMT

was 21.2 and 69.7 for Delta variant and 10.2 and 43.5 for Beta variant[8]. Of note, 278 (79%) subjects

in this study also participated in the primary series study with the data included. The geometric

mean ratio (GMR) with 95% CI were analyzed between the post-boosting levels/titres and post-

primary series levels/titres references. Unpaired t-test was used to compare GMC of the IgG

concentrations between groups using GraphPad Prism 9 version 9.2.0 (283) (GraphPad Software,

CA, USA). A p-value less than 0.05 is considered statistically significance. All statistical analyses

were conducted using STATA version 17 (Stata Corp, LP, College Station, TX, USA), SAS

Studio.

Data Availability

The datasets generated during and/or analyzed during the current study are available from

the corresponding author on reasonable request.

Acknowledgement

The authors gratefully acknowledge the Siriraj Institute of Clinical Research (SICRES)

team, Abbott Laboratories Ltd. for technical supports and all health care workers who took part

and enabled this study to be possible.

Author Contributions

N.A. and S.N. equally contributed to the research work. Conceptualization and

Methodology, N.A., S.N., J.S., and K.C.; Formal analysis and data curation: N.A., J.S., S.N. R.T;

Project administration, N.A, J.S., S.N.; Supervision, K.C.; Resources and Funding, K.C. All

involved with investigation, and writing-review and editing.

Conflict of Interest Declaration

All authors declare no personal or professional conflicts of interest, and no financial

support from the companies that produce and/or distribute the drugs, devices, or materials

described in this report.

Funding Disclosure

This study was supported by the National Research Council of Thailand. The Abbott Laboratories Ltd. partially supported the reagents for the anti-SARS-CoV-2 RBD IgG in this study.

References

1. Tanriover, M. et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *The Lancet* **398**, 213-222 (2021).

2. Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet* **397**, 99-111 (2021).

3. Jara, A. et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *New England Journal of Medicine* **385**, 875-884 (2021).

4. Lopez Bernal, J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine* **385**, 585-594 (2021).

5. Li, X. et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case–control real-world study. *Emerging Microbes & Infections* **10**, 1751-1759 (2021).

6. Mallapaty, S. China's Covid vaccines have been crucial - now immunity is waning. *Nature News* (2021). Available at: https://www.nature.com/articles/d41586-021-02796-w. (Accessed: 21st October 2021)

7. Angkasekwinai, N. et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers. Preprint at *medRxiv* https://doi:10.1101/2021.10.03.21264451 (2021).

8. Khoury, D. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature Medicine* **27**, 1205-1211 (2021).

9. Naaber, P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a

longitudinal prospective study. *The Lancet Regional Health - Europe* **10**, 100208 (2021).

10. Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca

vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in

England: test negative case-control study. *British Medical Journal* **373,** n1088 (2021).

11. AlQahtani, M. et al. Morbidity and mortality from COVID-19 post-vaccination breakthrough

infections in association with vaccines and the emergence of variants in Bahrain. Preprint at

Research Square https://doi.org/10.21203/rs.3.rs-828021/v1 (2021).

12. Borobia, A. et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-

primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2

trial. *The Lancet* **398**, 121-130 (2021).

13. Barros-Martins, J. et al. Humoral and cellular immune response against SARS-CoV-2

variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.

Preprint at *medRxiv* https://doi:10.1101/2021.06.01.21258172 (2021).

14. Gross, R. et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination

elicits potent neutralizing antibody responses and T cell reactivity. Preprint at *medRxiv*

https://doi:10.1101/2021.05.30.21257971 (2021).

15. Yorsaeng, R. et al. Immune response elicited from heterologous SARS-CoV-2 vaccination:

Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). Preprint at *medRxiv*

https://doi:10.1101/2021.09.01.21262955 (2021).

16. Nordström, P., Ballin, M. & Nordström, A. Effectiveness of heterologous ChAdOx1 nCoV-

19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A

nationwide cohort study. *The Lancet Regional Health - Europe* 100249 (2021).

17. Choi, A. et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters

in healthy adults: an interim analysis. *Nature Medicine* (2021).

18. Menni, C. et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of

the COVID Symptom Study app in the UK: a prospective observational study. *The Lancet*

Infectious Diseases **21**, 939-949 (2021).

19. Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous

and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *Nature Medicine* **27**, 1525-1529

(2021).

20. Folegatti, P. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against

SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The*

Lancet **396**, 467-478 (2020).

21. Ramasamy, M. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine

administered in a prime-boost regimen in young and old adults (COV002): a single-blind,

randomised, controlled, phase 2/3 trial. *The Lancet* **396**, 1979-1993 (2020).

22. Vályi-Nagy, I. et al. Comparison of antibody and T cell responses elicited by BBIBP-CorV

(Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult

humans. *GeroScience* **43**, 2321-2331 (2021).

23. Murugesan, K. et al. Interferon-γ Release Assay for Accurate Detection of Severe Acute

Respiratory Syndrome Coronavirus 2 T-Cell Response. *Clinical Infectious Diseases* **73**, e3130-

e3132 (2020).

24. Martínez-Gallo, M. et al. Commercialized kit to assess T-cell responses against SARS-CoV-

2 S peptides. A pilot study in Health Care Workers. Preprint at *medRxiv*

https://doi:10.1101/2021.03.31.21254472 (2021).

 Figure Legend

 Fig. 1 Adverse events following four different booster vaccinations. The stacked bars showed

 the percentage of participants who reported mild and moderate adverse events after the booster

 vaccinations in the subjects who had received 2-dose CoronaVac-primary series (A) and

 ChAdOx1-primary series (B) vaccination. Chi-square was used for statistical analyses and the *p*

 values were shown on the graphs.

 Fig. 2 Quantitation of anti-SARS-CoV-2 RBD IgG after booster vaccination. The scatter dot

 plot demonstrates the anti-SARS-CoV-2 RBD IgG concentration before and 2 weeks after

 different booster vaccination in the plasma of study subjects who had received 2-doses

 CoronaVac primary series **(A)** or ChAdOx1-primary series **(B)** 8-12 weeks prior. The numbers in

 the graph represent geometric mean and the error bars represent 95% confidence interval. The

 number of tested samples were indicated for each type for booster vaccine. The upper dotted line

 represents the geometric mean concentration (GMC) of anti-SARS-CoV-2 RBD IgG at 2 weeks

 after the second dose of the 2-dose primary series 4 weeks apart of CornaVac (A) and 8 weeks

 apart of ChAdOx1 (B) from reference Angkasekwinai N, et al. *medRxiv* preprint doi:

 https://doi.org/10.1101/2021.10.03.21264451, and the lower dot line represents the cut-off level

 for seropositivity. Indicated *p* values were for the unpair t test comparison between different

 types of booster vaccine and the pair t test comparison between before and after boost. The value

 of 11,360 BAU/mL was used for any samples that were reported> 11,360 BAU/mL by the

 machine. The scatter dot plot demonstrates the level of anti-SARS-CoV-2 RBD IgG at 2 weeks

 after various booster vaccination in the plasma of study subjects who had completed 2-doses of

 CoronaVac primary series (blue) or ChAdOx1 primary series (red) **(C)**. The numbers in the

graph represent GMC and the error bars represent 95% confidence interval. The number of tested

samples were indicated for each type for booster vaccine. Unpair t test was used to compare

between each group with indicated p value.

Fig. 3 Plaque reduction neutralisation test (PRNT$_{50}$) titres for SARS-CoV-2 delta and beta

variants after different booster vaccines. Scatter dot plots demonstrate PRNT$_{50}$ titre against

the **(A)** delta or **(B)** beta strain at 2 weeks after different booster vaccines in the study subjects

who had completed two doses of Coronavac or ChAdOx1 for 8-12 weeks. The PRNT$_{50}$ titre of

1:5 was used for all that were below the detectable level (< 1:10). The numbers in the graph

represent geometric mean titre (GMT) and the error bars represent 95% confidence interval (CI).

The upper dotted line represents the geometric mean values of anti-SARS-CoV-2 RBD IgG at 2

weeks after the second dose of the 2-dose primary series 4 weeks apart of CornaVac (A) and 8

weeks apart of ChAdOx1 (B) from reference Angkasekwinai N, et al. *medRxiv* preprint doi:

https://doi.org/10.1101/2021.10.03.21264451; and the lower dot line represents the cut-off level

for seropositivity. Unpaired t tests were used for statistical analyses and the p values were

indicated. **(C)** comparison of the plaque reduction neutralisation test (PRNT$_{50}$) titres for the

SARS-CoV-2 delta and beta variants after different booster vaccine in among each primary

series. Aligned dot plots show the PRNT$_{50}$ titre against the delta (teal) or beta (pink) variant in

the plasma of study subjects who had completed two doses of CoronaVac or ChAdOx1 at 2

weeks after booster with BBIBP-CorV, ChAdOX1, 30 $\boldsymbol{\mu}$g. BNT162b2 and 15 $\boldsymbol{\mu}$g. BNT162b2.

The PRNT$_{50}$ titre of 1:5 was used for all that were below the detectable level (< 1:10). Ratio

paired t test was used for statistical analyses.

Fig. 4 Correlation between the level of anti-SARS-CoV-2 RBD IgG and plaque reduction neutralisation test (PRNT$_{50}$) titres for the SARS-CoV-2 delta and beta variants. Dot plots show the correlation between the level of anti-SARS-CoV-2 RBD IgG and PRNT$_{50}$ titre against the **(A, B)** delta or **(C, D)** beta variant in the plasma of study subjects who had completed two doses of CoronaVac or ChAdOx1 at 2 weeks after booster with BBIBP-CorV (green), ChAdOX1 (red), 30 $\boldsymbol{\mu}$g. BNT162b2 (orange) and 15 $\boldsymbol{\mu}$g. BNT162b2 (yellow). The PRNT$_{50}$ titre of 1:5 was used for all that were below the detectable level (< 1:10). Pearson's correlation coefficient (r) with p value for each booster vaccine was indicated.

Supplementary Fig S1. Comparison of the cellular immune responses after different booster vaccine among each primary series by interferon-gamma (IFNγ) releasing assay (IGRA). Scatter dot plots show the level of IFNγ production in the blood after being stimulated with either Ag1 or Ag2 before booster vaccination **(A)**. The blood samples were collected at 8-12 weeks after two doses of CoronaVac or ChAdOx1. Mann-Whitney test was used for statistical analyses. **Comparison of the cellular immune responses after different booster vaccine among each primary series by IGRA in those who were seronegative before booster vaccination.** Aligned dot plots show the level of IFNγ production in the blood after being stimulated with either **(B)** Ag1 or **(C)** Ag2 comparing between before (teal) and 2 weeks after (pink) booster with BBIBP-CorV, ChAdOX1, 30 $\boldsymbol{\mu}$g BNT162b2 and 15 $\boldsymbol{\mu}$g BNT162b2. Wilcoxon matched-pairs signed rank test was used for statistical analyses. Median and interquartile range (IQR) of each group are indicated. Ag.1 was derived from SARS-CoV-2 S peptide for CD4+ T cell stimulation and Ag.2 was for CD8+ T cells stimulation. Interferon-gamma (IFN-Υ) concentration in the plasma fraction was measured with an automated

533   QuantiFERON SARS-CoV-2 ELISA instrument for research use only (RUO) and reported in

534   international Units per mL (IU/mL).

 Table 1 Characteristics of 352 participants classified by primary series vaccination.

Demographics	Type of booster vaccinations				
CoronaVac-prime (n=179)					
	BBIBP-CorV n=14	ChAdOx1 n=65	30 µg BNT162b2 n=50	15 µg BNT162b2 n=50	*p*-value
Age (years), median (IQR)	31 (27, 41.5)	36.6 (29.5, 44)	32 (28, 41.8)	40 (31.5, 45.3)	0.018
Female, n (%)	12 (85.7)	51 (78.5)	40 (80.0)	33 (66.0)	0.249
BMI (kg/m^2), median (IQR)	25.2 (21.1, 31.6)	23.4 (20.9, 27.1)	22.1 (19.5, 25.5)	23.9 (20.9, 26.0)	0.325
Anti-RBD IgG GMC at baseline (95%CI)	34.32 (22.33, 52.77)	38.18 (31.21, 46.71)	33.31 (26.72, 41.53)	37.67 (31.65, 44.84)	0.7616
Anti-RBD IgG GMC after boosting (95%CI)	154.6 (92.11, 259.47)	1358.0 (1141.84, 1615.07)	5152.2 (4491.65, 5909.83)	3981.1 (3397.15, 4665.42)	<0.0001
Baseline SARS-CoV-2 IGRA positive, n (%)	5 (35.7)	12 (18.5)	16 (32)	12 (24)	0.301

	BBIBP-CorV n=23	ChAdOx1 n=50	30 µg BNT162b2 n=50	15 µg BNT162b2 n=50	p-value
Post-boosting IGRA positive among baseline negative participants, n (%)	1/9 (11.1)	26/53 (49.1)	28/34 (82.4)	30/38 (79.0)	<0.0001
ChAdOx1-prime (n=173)					
Age (years), median (IQR)	51 (42, 59)	45.5 (36, 57)	34 (30, 43)	41.5 (34, 49.5)	0.001
Female, n (%)	21 (91.3)	47 (94.0)	37 (74.0)	44 (88.0)	0.001
BMI (kg/m^2), median (IQR)	24.8 (22.4, 27.6)	23.8 (21.3, 26.7)	21.4 (19.3, 24.7)	23.3 (20.4, 26.5)	0.001
Anti-RBD IgG at baseline (95%CI)	106.6 (70.89, 160.29)	105.7 (80.97, 137.97)	95.98 (75.84, 121.45)	90.11 (73.62, 110.30)	0.7661
Anti-RBD IgG GMC after boosting (95%CI)	128.1 (93.52, 175.37)	246.4 (199.59, 304.20)	2363.8 (2005.58, 2786.06)	1961.9 (1624.61, 2369.10)	<0.0001
Baseline SARS-CoV-2 IGRA positive, n (%)	13 (56.5)	26 (52.0)	9 (18.0)	14 (28.0)	<0.0001

| Post-boosting IGRA positive among baseline negative participants, n (%) | 0/10 | 0/24 | 31/41 (75.6) | 24/26 (66.7) | <0.0001 |

557   GMC: geometric mean concentration; IGRA: QuantiFERON SARS-CoV-2 interferon gamma release assay

 Table 2 The 50% plaque reduction neutralization (PRNT$_{50}$) geometric mean antibody titers

 (GMT) and the geometric mean ratio (GMR) between post-boosting and post-primary

 series*.

PRNT$_{50}$ GMT	Type of booster vaccinations				
CoronaVac-prime (n=104)					
	BBIBP-CorV n=14	ChAdOx1 n=30	30 µg BNT162b2 n=30	15 µg BNT162b2 n=30	*p*-value
GMT (95% CI) against Delta variant	61.3 (35.07, 107.02)	271.2 (222.54, 330.49)	411.1 (311.71,542.16)	499.12 (418.54, 595.21)	<0.0001
GMR (95% CI) between post-boosting and post-primary series* against Delta variant	2.89 (1.52, 5.50)	12.79 (9.06, 18.06)	19.39 (13.04, 28.84)	23.54 (16.89, 32.82)	<0.0001
GMT (95% CI) against Beta variant	37.2 (18.00, 76.91)	170.5 (124.65, 233.13)	306.7 (221.44, 424.71)	322.8 (239.34, 435.25)	<0.0001
GMR (95% CI) between post-boosting and post-primary series* against Beta variant	3.65 (1.65, 8.08)	16.72 (11.11, 25.15)	30.07 (19.79, 45.69)	31.65 (21.27, 47.09)	<0.0001
ChAdOx1-prime					

	BBIBP-CorV n=22	ChAdOx1 n=30	30 μg BNT162b2 n=30	15 μg BNT162b2 n=30	p-value
GMT (95% CI) against Delta variant	49.0 (37.56, 64.05)	69.1 (50.14, 95.14)	470.1 (395.49, 558.89)	358.4 (276.13, 465.26)	<0.0001
GMR between post-boosting and post-primary series* (95% CI) against Delta variant	0.70 (0.44, 1.12)	0.99 (0.60, 1.63)	6.74 (4.45, 10.23)	5.14 (3.24, 8.16)	<0.0001
GMT (95% CI) against Beta variant	28.1 (18.08, 43.53)	38.2 (26.06, 56.05)	292.9 (233.73, 367.17)	250.0 (182.95, 341.51)	<0.0001
GMR (95% CI) between post-boosting and post-primary series* against Beta variant	0.65 (0.36, 1.15)	0.88 (0.52, 1.49)	6.73 (4.42, 10.26)	5.75 (3.57, 9.24)	<0.0001

*The post primary series GMC was derived from the study in the same setting as the current study

(Reference: Angkasekwinai, N. et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against

the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers.

Preprint at *medRxiv* https://doi:10.1101/2021.10.03.21264451 (2021)). The post primary series GMT

(95% CI) at 2 weeks after the second dose of the 2-dose homologous CoronaVac, 4 weeks apart, were

21.2 (16.07, 27.87) and 10.2 (7.92, 13.12) against Delta and Beta variants, respectively; and after 2-dose

homologous ChAdOx1,10 weeks apart, were 69.7 (48.08, 101.00) and 43.5 (30.73, 61.72) against Delta

and Beta variants, respectively.

609 **Supplementary Table 1 Adverse events of following booster vaccination.**

Adverse events (AEs)	BBIBP-CorV	ChAdOx1	30 µg BNT162b2	15 µg BNT162b2	p-value
CoronaVac-prime (n=179)	n=14	n=65	n=50	n=50	
Overall AEs (%)	10 (71.43)	64 (98.46)	46 (92.0)	40 (80.0)	0.002
Injection site reaction (%)	9 (64.29)	62 (95.38)	46 (92.00)	36 (72.00)	<0.001
Fatigue (%)	2 (14.29)	46 (70.77)	26 (52.0)	10 (20.00)	<0.001
Headache (%)	1 (7.14)	12 (18.46)	25 (50.0)	18 (36.0)	<0.001
Myalgia (%)	6 (42.86)	54 (83.08)	2 (4.0)	1 (2.0)	<0.001
Malaise (%)	0	1 (1.54)	31 (62.0)	20 (40.0)	<0.001
Nausea (%)	2 (14.29)	20 (30.77)	7 (14.0)	5 (10.0)	0.119
Diarrhea (%)	1 (7.14)	12 (18.46)	3 (6.0)	6 (12.0)	0.284
Fever (%)	1 (7.14)	25 (38.46)	4 (8.0)	1 (2.0)	<0.001
Rash (%)	2 (14.29)	9 (13.85)	7 (14.0)	2 (4.0)	0.341
Somnolence (%)	0	0	2 (4.0)	2 (4.0)	0.357
Flu-like symptoms (%)	0	4 (6.15)	1 (2.0)	1 (2.0)	0.453
Arthralgia (%)	0	2 (3.08)	1 (2.0)	1 (2.0)	0.906
Dizziness (%)	0	1 (1.54)	1 (2.0)	0	0.758
Paresthesia (%)	2 (14.29)	1 (1.54)	1 (2.0)	0	0.014
Vomiting (%)	0	4 (6.15)	0	1 (2.0)	0.199
ChAdOx1-prime (n=173)	n=23	n=50	n=50	n=50	

Overall AEs (%)	14 (60.87)	36 (72.0)	49 (958.0)	44 (89.0)	<0.001
Injection site reaction (%)	9 (39.13)	28 (56.0)	47 (94.00)	44 (88.00)	<0.001
Fatigue (%)	3 (13.04)	18 (36.0)	34 (68.0)	20 (40.00)	<0.001
Headache (%)	6 (26.09)	15 (30.0)	28 (56.0)	28 (56.0)	0.024
Myalgia (%)	6 (42.86)	54 (83.08)	2 (4.0)	1 (2.0)	<0.001
Malaise (%)	7 (30.43)	21 (42.0)	34 (68.0)	37 (74)	0.001
Nausea (%)	1 (4.35)	20 (30.77)	7 (14.0)	5 (10.0)	0.102
Diarrhea (%)	1 (4.35)	5 (10.0)	8 (16.0)	6 (10.0)	0.834
Fever (%)	1 (4.35)	2 (4.0)	4 (8.0)	1 (2.0)	0.240
Rash (%)	0	1 (2.0)	1 (2.0)	0	0.688
Somnolence (%)	0	1 (2.0)	2 (4.0)	0	0.421
Flu like symptoms (%)	0	1 (2.0)	2 (4.0)	2 (4.0)	0.738
Arthralgia (%)	0	0	0	1 (2.0)	0.480
Dizziness (%)	2 (8.70)	1 (2.0)	0	0	0.118
Paresthesia (%)	0	0	0	0	-
Vomiting (%)	0	3 (6.0)	0	0	0.057

618 **Supplementary Table 2 The geometric mean anti-RBD IgG concentration (GMC) and the**

619 **geometric mean ratio (GMR) between post boosting and baseline or post primary series*.**

Anti-RBD IgG antibody concentration (GMC)	Type of booster vaccinations				
CoronaVac-prime (n=179)					
	BBIBP-CorV n=14	ChAdOx1 n=65	30 µg BNT162b2 n=50	15 µg BNT162b2 n=50	*p*-value between groups
GMC at baseline (95%CI)	34.32 (22.33, 52.77)	38.18 (31.21, 46.71)	33.31 (26.72, 41.53)	37.67 (31.65, 44.84)	0.7616
GMC after boosting (95%CI)	154.6 (92.11, 259.47)	1358.0 (1141.84, 1615.07)	5152.2 (4491.65, 5909.83)	3981.1 (3397.15, 4665.42)	<0.0001
GMR between post-boosting and baseline (95% CI)	4.5 (2.98, 6.80)	35.6 (29.18, 43.34)	154.7 (124.30, 192.50)	105.7 (90.31, 123.68)	<0.0001
GMR between post-boosting and post primary series of CoronaVac*	0.94 (0.53, 1.67)	8.26 (6.29, 10.85)	31.34 (24.37, 40.30)	24.22 (18.60, 31.54)	<0.0001
ChAdOx1-prime (n=173)					

	BBIBP-CorV n=23	ChAdOx1 n=50	30 µg BNT162b2 n=49	15 µg BNT162b2 n=50	*p*-value between groups
Geometric mean level at baseline (95%CI)	106.6 (70.89, 160.29)	105.7 (80.97, 137.97)	95.98 (75.84, 121.45)	90.11 (73.62, 110.30)	0.7661
Geometric mean level after boosting (95%CI)	128.1 (93.52, 175.37)	246.4 (199.59, 304.20)	2363.8 (2005.58, 2786.06)	1961.9 (1624.61, 2369.10)	<0.0001
GMR between post-boosting and baseline (95% CI)	1.2 (1.01, 1.43)	2.3 (1.92, 2.83)	25.1 (20.30, 31.01)	21.8 (18.28, 25.92)	<0.0001
GMR between post-boosting and post primary series of ChAdOx1*	0.46 (0.28, 0.65)	0.88 (0.58, 1.13)	8.49 (5.71, 10.44)	7.04 (4.69, 8.84)	<0.0001

*The post primary series GMC was derived from the study in the same setting as the current study

(Reference: Angkasekwinai, N. et al. Safety and Immunogenicity of CoronaVac and ChAdOx1 Against

the SARS-CoV-2 Circulating Variants of Concern (Alpha, Delta, Beta) in Thai Healthcare Workers.

Preprint at *medRxiv* https://doi:10.1101/2021.10.03.21264451 (2021)). The post primary series GMC

(95% CI) at 2 weeks after the second dose of the 2-dose homologous CoronaVac, 4 weeks apart, was

164.4 (133.55, 202.43); and after 2-dose homologous ChAdOx1,10 weeks apart, was 278.5

(195.66,396.33).

A

B

C